Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194019 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL14929306 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL325079 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL12374613 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11982565 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL16884139 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL1739854 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11965635 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL24672314 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL8815319 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166623-A1 | NOVEL PROCESS | ARTIOS PHARMA LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| CN-117062799-A | New method | 阿提奥斯医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-8580751-B2 | Esterified α-galactosylceramide | RIKEN (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | RIKEN (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166623-A1 | NOVEL PROCESS | UGT1A1, CYP1B1, BRCA1 | CA2 4776/4885CA1 4716/4885CA9 3978/4885 |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | GBA1, UGCG, MAN2B1 | CA2 185/4885CA1 207/4885CA9 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.